State of the evidence: Evidence level: small randomized, double-blind, placebo-controlled human trial; no significant benefit was demonstrated in the cardiovascular measures studied.
The central finding in humans
A 2021 double-blind, placebo-controlled study randomized 68 adults with hypertension and elevated galectin-3; 52 completed the final visit. After six months, MCP showed no significant advantage in collagen markers, echocardiographic diastolic measures or arterial stiffness.[1] These findings do not provide a basis for promising cardiovascular benefit.
Why the placebo comparison matters
A measurement changing from baseline does not, by itself, show an effect caused by a product. A control group helps establish what happened during the same period among people undergoing similar assessments. This shifts attention from a change within one group to the difference between groups. Understanding the comparison can be more informative than reading an isolated percentage change.
Name the outcomes accurately
Laboratory and imaging assessments in this study are intermediate indicators of biological processes. A biomarker study does not ask the same question as a trial evaluating heart attacks, hospital admissions or survival. A discussion framed around heart health should not imply that every cardiovascular condition or clinical outcome was investigated. Keep the measured endpoints visible and distinguish them from outcomes readers may assume were studied.
How to interpret a negative result
Failure to find a significant difference means benefit was not demonstrated under the conditions studied. It need not be expanded into a universal claim that no effect could ever occur in any population. A balanced interpretation rejects unsupported promises while leaving genuinely different research questions open. Uncertainty, however, cannot be presented as though it were positive evidence of benefit.
Study size and incomplete follow-up
When not everyone completes the final assessment, handling missing information becomes important. Sample size and follow-up duration influence the differences a study can evaluate confidently. A practical reading method is to locate the numbers who entered, completed and were analyzed. These details are not reasons to dismiss the research; they help determine the strength and precision of the conclusion it can support.
Putting the study into a care discussion
An article about a supplement is not an independent reason to change blood-pressure or heart treatment. A clinical conversation can address the exact preparation, existing medicines and the benefit being sought. Asking which outcome would be expected to improve, and how it would be assessed, turns a broad mechanistic claim into a concrete clinical question. The available trial does not substantiate a cardiovascular-benefit promise.
References
This article provides general health information. Research findings about MCP are not individual recommendations for diagnosing or treating disease. Medicine and supplement use should be discussed with a doctor or pharmacist.
Published and sources assessed: 17 October 2026